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Abstract
Background: Approximately 6.2 % of women in the USA and 3.7 % of women in the UK, use Selective Serotonin
Reuptake Inhibitors (SSRIs) during their pregnancies because of depression and/or anxiety. In the Netherlands, this
prevalence is around 2 %. Nonetheless, SSRI use during pregnancy is still controversial. On the one hand SSRIs may
be toxic to the intrauterine developing child, while on the other hand relapse or recurrence of depression during
pregnancy poses risks for both mother and child. Among patients and professionals there is an urgent need for
evidence from randomized studies to make rational decisions regarding continuation or tapering of SSRIs during
pregnancy. At present, no such studies exist.
Methods/Design: ‘Stop or Go’ is a pragmatic multicentre randomized non-inferiority trial among 200 pregnant
women with a gestational age of less than 16 weeks who use SSRIs without clinically relevant depressive
symptoms. Women allocated to the intervention group will receive preventive cognitive therapy with gradual,
guided discontinuation of SSRIs under medical management (STOP). Women in the control group will continue the
use of SSRIs (GO). Primary outcome will be the (cumulative) incidence of relapse or recurrence of maternal
depressive disorder (as assessed by the Structured Clinical Interview for DSM disorders) during pregnancy and up to
three months postpartum. Secondary outcomes will be child outcome (neonatal outcomes and psychomotor and
behavioural outcomes up to 24 months postpartum), and health-care costs. Total study duration for participants will
be therefore be 30 months. We specified a non-inferiority margin of 15 % difference in relapse risk.
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Discussion: This study is the first to investigate the effect of guided tapering of SSRIs with preventive cognitive
therapy from early pregnancy onwards as compared to continuation of SSRIs during pregnancy. We will study the
effects on both mother and child with a pragmatic approach. Additionally, the study examines cost effectiveness. If
non-inferiority of preventive cognitive therapy with guided tapering of SSRIs compared to intended continuation of
SSRIs is demonstrated for the primary outcome, this may be the preferential strategy during pregnancy.
Trial registration: Netherlands Trial Register (NTR): NTR4694; registration date: 16-jul-2014
Keywords: Pregnancy, Antidepressants, Selective serotonin reuptake inhibitors, SSRI, Depression, Prevention,
Relapse, Recurrence, Cognitive therapy, Perinatal outcome, Cost-effectiveness
Background
Depressive disorder and anxiety disorders are the
primary indications for the use of Selective Serotonin
Reuptake Inhibitors (SSRIs). Worldwide, the SSRI
prescription rate during pregnancy ranges from
6.2 % in the USA [1], to 3.7 % in the UK [2]. The
actual Dutch nationwide estimated use of SSRIs dur-
ing pregnancy is about two percent [3, 4]; while in the
Rotterdam area this number is even as high as five percent
[5]. Nonetheless, SSRI use during pregnancy is still con-
troversial. On the one hand SSRIs may be toxic to the
intrauterine developing child, while on the other hand,
relapse of depression and/or anxiety during pregnancy
poses risks for both mother and child [6].
The preventive effect of SSRIs for relapse of depres-
sion during pregnancy seems equivocal. One naturalistic
study showed a significant increased risk of relapse in
pregnant women who discontinued their medication
compared to continuing medication (68 % vs. 26 %),
while another naturalistic study showed no clear differ-
ence relapse rates of depression (16 % in total) between
pregnant women continuing or discontinuing antide-
pressants [7, 8].
Pregnancy-related complications both exist for women
using SSRIs during pregnancy and women with un-
treated depression/anxiety during pregnancy, posing a
dilemma for the treating physician who considers SSRI
withdrawal. For example, studies found significantly
increased risks for preeclampsia among women who use
SSRIs and increased risks for pregnancy-induced hyper-
tension in women with depression/anxiety during preg-
nancy compared to healthy controls [9, 10].
Whether or not SSRIs are of direct influence on the
newborn, both short- and long-term, is another unre-
solved issue. For example, a recent meta-analysis showed
an increased risk for cardiovascular malformations (RR =
1.36) and septal heart defects (RR = 1.40) with use of
SSRIs [11]. These findings were however not supported by
a recent Nordic cohort study, which – after a sibling
controlled analysis – found no substantial increase in
prevalence of overall cardiac birth defects for any SSRI
(OR = 0.92) [12]. Another example of evidence of a poten-
tial direct toxic effect is the association of SSRI use with
persistent pulmonary hypertension (PPHN) of the neo-
nate. A large cohort study from the Scandinavian national
health registers showed a twofold-increased risk of PPHN
with exposure later than gestational week 20 (OR = 2.1)
[13]. However, this risk appeared more modest (OR =
1.51) in a large cohort study from 46 US states [14].
Several other effects of SSRIs during pregnancy have
been described, such as a higher risk of poor neonatal
adaptation (OR = 5.07), respiratory distress (OR = 2.20),
tremors (OR = 7.89), preterm delivery and small for gesta-
tional age, lower birth weight and lower Apgar scores at 1
and 5 min after birth [15, 16]. Long-term effects on chil-
dren are less often investigated. One systematic review
found an adverse effect on children’s motor development
but not on emotional or behavioural development [17].
Two large studies reported on the association between
maternal SSRI use and childhood autism spectrum disor-
ders, but found conflicting results [18, 19].
On the other hand, leaving depression or anxiety disor-
ders untreated may be hazardous to the unborn child as
well. At present, it is well known that children of women
who suffered from anxiety or depression during pregnancy
have an increased risk of adverse perinatal health out-
comes, and behavioural, emotional, cognitive, and motor
problems in early childhood [20, 21]. It is also shown that
the infant cortisol stress response is altered if the mother
suffered from depression during pregnancy [22]. One
meta-analysis showed an association of depression during
pregnancy with preterm birth and low birth weight [23].
Another more recent meta-analysis showed that depres-
sion during pregnancy is associated with premature deliv-
ery, but did not find associations with birth weight,
neonatal intensive care unit admissions, preeclampsia,
gestational age or Apgar scores [24].
Overall, in clinical practice and literature, pregnant
women express a strong preference for non-pharmacologic
treatment of depression over antidepressant medication
[25]. Hence, cognitive behavioural therapy (CBT) could be
a good alternative for SSRI use during pregnancy.
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According to a recent meta-analysis there is strong evi-
dence that CBT interventions are effective for preventing
depressive relapse during the perinatal period [26]. A recent
follow-up study showed that preventive cognitive therapy
(PCT) has long-term effects in preventing depressive re-
lapse in patients with recurrent depression for over 5.5-10
years after the sessions ended [27, 28]. This preventive psy-
chological strategy therefore seems promising in preventing
depressive relapse, presumably also during pregnancy.
Moreover, a recent study in the UK among non-pregnant
patients showed that tapering antidepressants with therapy
was as effective as continuation of antidepressants (Hazard
Ratio 0.89) [29]. Nevertheless, further investigation is ne-
cessary to assess effectiveness of tapering antidepressants
with added PCT during the perinatal period.
In conclusion, pregnant women and their clinicians face
a dilemma, which is widely experienced in current prac-
tice [30]. At present, there are no suitable data available to
guide evidence based decisions on SSRI continuation or
discontinuation during pregnancy [31]. Both the National
Institute for Health and Clinical Excellence in the United
Kingdom (NICE) guideline [32], and American Psychiatric
Association (APA) [33] therefore recommend to discuss
both possibilities with women. The recently developed
Dutch multidisciplinary guideline advises to continue SSRI
use during pregnancy, and furthermore advises a hospital
delivery and neonatal observation based on the increased
risk and the severity of the (rare) condition of PPHN and
prevalence (25–30 %) of children with neonatal abstinence
after maternal SSRI use [34]. Nonetheless, the need of ran-
domized trials was stressed. Indeed, existing studies are
observational and therefore their results do not fully allow
causal inference nor definite conclusions for practice.
Trial objectives
In this randomized controlled trial (RCT), the effect of
preventive cognitive therapy (PCT) with guided tapering
of SSRIs in early pregnancy will be compared to continu-
ation of SSRIs during pregnancy. We will study effects on
both mother and child with a pragmatic approach. The
expectation is that tapering of SSRIs with added PCT does
not increase the risk of clinically relevant maternal relapse
or recurrence1 of depression or onset of anxiety disorders
during pregnancy up to three months postpartum in ex-
cess of [absolute] 15 % compared to continuation of
SSRIs. If so, discontinuation is deemed non-inferior with
regard to relapse/recurrence risk. Furthermore, we expect
that tapering of SSRIs is better than continuation of SSRIs
with respect to child development. Finally, but not unim-
portantly, we hypothesize that discontinuation will de-
crease total costs per woman and child on a 3 months and
projected long term base, assuming no relevant effects of
discontinuation on the mother and no effects on the child
are found.
Methods/Design
Design & setting
The Stop or Go study is a pragmatic multi-centre ran-
domized controlled non-inferiority trial (RCT) in obstet-
ric care. Women will be recruited during their first
prenatal visit in midwifery practices (first echelon care)
and hospitals (second and third echelons care), or
through advertisement in (social) media. After inclusion,
women will be randomly allocated into two groups:
STOP or GO. Both groups will receive regular assess-
ments throughout their pregnancy and up to 3 months
post-partum. Permission will be asked to contact the
Centre of Childhood (CJG) at 24 months after delivery
for information on the development of the child. Total
duration of the study for participants will therefore be
30 months. In Fig. 1 an overview of the study design and
main procedures is shown.
Participants
Women who are less than 16 weeks pregnant and use a
SSRI primarily for depressive disorder, and are currently
at least in remission or recovered [35], are invited to par-
ticipate in the trial. Exclusion criteria are multiple preg-
nancy, as these women have a markedly increased
obstetric risk, thereby threatening the homogeneity of the
study population and thus potentially complicate the stat-
istical analysis, and insufficient proficiency in Dutch or
English, since our intervention is not yet available in other
languages. Also, women will be excluded with severe med-
ical conditions, such as oncology-related conditions or
conditions that need urgent medical interventions, which
involve treatment decisions overriding research participa-
tion. Exclusion criteria related to mental health are:
current mania or hypomania or a history of bipolar illness,
suicidality and serious self harm, any psychotic disorder
(current and previous), current alcohol or drug misuse,
predominant anxiety disorders and personality disorders
that require psychotherapeutic treatment for more than 2
sessions a month.
Assessment of eligibility
After informed consent is obtained, a pre-assessment
interview will be conducted, with the Structured Clinical
Interview for DSM-disorders (SCID) [36] and the
Hamilton Depression Rating Scale (HDRS) [37] to assess
major DSM-IV Axis I psychiatric diagnoses and actual
remission status and depressive symptoms respectively.
Before randomization, study researchers will contact the
medical professional who prescribed the SSRI medica-
tion to inform the professional about the study and dis-
cuss exclusion criteria as described above for study
participation.
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Recruitment through midwifery practices (first echelons care) and hospitals (second and third echelons
care), and approaching the general population using (social) media.
Screening: SSRI use and pregnancy duration.
Exclusion:
No SSRI use
More than 16 weeks pregnant
Declines to participate.
Randomization (1:1) by a web based computer-generated randomization program.
STOP-group: Guided tapering of
SSRI according to protocol with
preventive cognitive therapy.
GO-group: Continuation of SSRI
(treatment as usual).
Assessment at 24 and 36 weeks of pregnancy (T2, T3), delivery (T4), and 4 and 12 weeks after 
delivery (T5, T6). 
See Table 1 for an overview of the assessments. Assessments include questions on anxiety 
symptoms, depressive symptoms, childhood trauma, affect, dysfunctional attitudes, medication 
beliefs, medication adherence, quality of life, and health costs. 
Both groups receive obstetric care as usual.
Pre-assessment (T0): SCID and HRDS telephone interview, baseline questionnaires (T1). 
Exclusion:
Current depression as defined by
HRDS (score >13) and/or SCID
No MDD in history
Severe comorbid psychiatric 
disorder
Severe comorbid medical condition.
Monitoring possible withdrawal
symptoms.
Fig. 1 Study flow chart
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Randomisation
Two hundred women will be randomized in a 1:1 alloca-
tion ratio to either the intervention arm (STOP) or the
care as usual arm (GO). Randomization will be done
with a web based computer-generated randomization
schedule (a validated TENALEA Clinical Trial Data
Management System; http://www.formsvision.com/)
using permuted blocks of random size with a maximum
of 16 and stratified for the number of previous depres-
sive episodes (dichotomized). Based on a recent review
[35], the participants are divided into groups of partici-
pants with 3 or less previous depressive episodes, versus
4 or more. Allocation of participants is concealed for
study researchers.
Interventions
Tapering SSRI
Women assigned to discontinuation of SSRIs will be re-
ferred to a psychiatrist trained in guiding tapering of
SSRIs during pregnancy. They will plan and carry out
SSRI discontinuation using an expert-based discontinu-
ation protocol [38]. The aim is to taper the use of SSRIs
within four weeks, depending on patient preferences
and on drug characteristics (e.g., half-life in the body).
There are no restrictions on the use of medication
like sleeping pills, paracetamol, and mild tranquil-
lizers. All co-medication will be monitored during the
study period.
Preventive cognitive therapy
Trained psychologists will provide preventive cognitive
therapy in the discontinuation arm. This psychological
intervention has proven to be effective in relapse pre-
vention [27, 39–42]. The current manual was evaluated
in previous studies [27, 38, 41, 43].
The intervention will be applied through VSee (http://
www.vsee.com), a HIPAA-compliant telehealth app. Sev-
eral studies demonstrated that psychological interven-
tion as applied by telephone support is effective and
there is some evidence that it might be effective to de-
crease postpartum depressive symptomatology [44–47].
Although not tested during pregnancy, there are indica-
tions that antenatal telephone or online therapy is effect-
ive and convenient [48].
The preventive psychological intervention consists of a
minimum of eight weekly VSee sessions. These sessions
are led by professional psychologists trained in cognitive
behavioural therapy and may occur at any time of the
day. The focus of the sessions is on identifying and
teaching the participants to challenge dysfunctional be-
liefs, enhance recall of positive feelings and cognitions
and a personal prevention plan is developed in which it
is specified how the participant can prevent a depressive
episode in the future. For each session the participant
will receive some assignments of approximately 10 min
per day. Treatment adherence will be monitored.
Care as usual
Women assigned to continuation of SSRIs (GO) obtain
usual care. They will be instructed to consult their doc-
tor as they regularly do, in line with the pragmatic na-
ture of the study. All the care that is provided will be
monitored.
Outcome measures
Mother
Primary outcome of this trial is (cumulative) incidence of
relapse or recurrence of a depressive episode (as defined
by the SCID-I [36]) during pregnancy and up to 12 weeks
postpartum. The SCID-I is assessed at baseline (T0) and
12 weeks postpartum (T6). If – based on assessment with
the HDRS at fixed time-points – relapse/recurrence is
suspected, the SCID-I will be performed intermittently.
For registration of severity of depressive symptoms,
the HDRS will telephonically be assessed additionally, at
baseline (T0), at 36 weeks of gestation (T3), and
12 weeks postpartum (T6), and also intermittently, if ne-
cessary [37]. When the HDRS at any stage turn out
above cut-off scores, the participant will be called one week
after initial measurement. The HDRS will be repeated to
confirm or reject elevated scores. An adjusted telephonic
version of the everyday problem checklist (EPCL) and preg-
nancy related life events will be assessed during each tele-
phonic measurement (T0, T2, T3, T5 and T6).
Women will be asked to fill in questionnaires during five
occasions: baseline (T1), 24 and 36 weeks of gestation (T2
and T3), and 4 and 12 weeks postpartum (T5 and T6). The
questionnaires differ in composition at the five measure-
ment moments, as shown in Table 1. During these occa-
sions, participants are variably asked to report on anxiety
symptoms (Dutch version of the State Trait Anxiety Inven-
tory STAI), short and long version [49, 50]), depressive
symptoms (the Dutch version of the Edinburgh Postnatal
Depressions Scale; EPDS [51]), childhood trauma (Child-
hood Trauma Questionnaire; CTQ [52]), affect (the Inter-
national Short-Form of the Positive and Negative Affect
Schedule; I-PANAS-SF [53]), dysfunctional attitudes (Dys-
functional Attitude Scale; DAS [54]), medication beliefs
(Beliefs about Medicines Questionnaire; BMQ [55]), medi-
cation adherence (Medication Adherence Rating Scale;
MARS [56]) and Quality of Life (EQ-5D-5L [57]). Socioeco-
nomic position, ethnicity, smoking behaviour, alcohol use,
family history and information on previous pregnancies
and family size will be assessed using the Mind2Care ques-
tionnaire [58], a screen-and-advice instrument to detect
mental health problems among pregnant women.
Health care cost data is registered using the TIC-P
[59]. This instrument allows reliable recall over the past
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six months [60]. We will adapt scoring for ‘normal’ ab-
senteeism and sickness leave for pregnant and recently
delivered women. Care will be taken for secondary ef-
fects on child-care for other children (if present) in case
of postpartum hospitalisation.
Using the Discontinuation Emergent Signs and Symp-
toms checklist (DESS) [61], the discontinuation group
will be monitored by telephone weekly during tapering,
to collect information about dosages and potential
symptoms of withdrawal. Both groups will receive tele-
phonic monitoring of medication use, including psychi-
atric co-medication, at 24 and 36 weeks of gestation (T2
and T3) and 4 and 12 weeks postpartum (T5 and T6).
Alongside the self-report measures, several sources of
biological materials will be collected during the study.
At baseline, immediately after delivery and 12 weeks
postpartum (T1, T4 and T6) we will collect maternal
hair strands to measure cortisol levels. Hair cortisol is a
validated biomarker for long-term cortisol exposure and
makes it possible to create a timeline of cortisol expos-
ure during follow-up [62]. At baseline a maternal buccal
swab will be collected in order to enable epigenetic and
pharmacogenetic analysis. Maternal blood sampling will
be performed 12 weeks postpartum (T6) to enable add-
itional epigenetic and pharmacogenetic testing, but also
for measurement of SSRI concentration and immuno-
logical factors.
Health care professional
We will send a Case Report Form (CRF) to the partici-
pant’s obstetric caregiver, either a midwife or a gynaecolo-
gist, to request information about the pregnancy and
delivery. Complications during pregnancy and delivery,
such as hypertensive disorders or pregnancy, foetal growth
retardation, preterm labour, induced labour and caesarean
section will be registered as well as information about the
neonate (e.g., Apgar scores, birth weight, congenital mal-
formations and admission to paediatric ward).
Table 1 Assessment per measurement moment
Method T0 T1 T2 T3 T4 T5 T6 T7
Clinical Diagnostic Interview (SCID-I) Int X … … … … X
Depressive symptoms (HDRS) Int X … X … … X
Peripartum depression (EPDS) SR X X X X X
Anxiety (STAI) SR X X X X X
Affect (I-PANAS-SF) SR X X X X X
Attitudes (DAS) SR X X X
Daily hassles Int X X X X X
Life events Int X X X X X
Sociodemographic & -economic
factors (Mind2Care)
SR X
Substance use (Mind2Care) SR X X X X X
Medication use Int X X X X X
Medication adherence SR X
Medication beliefs SR X
Childhood trauma (CTQ) SR X
Quality of Life (EQ-5D-5L) SR X X X X X
Health care consumption (TIC-P) SR X X X X
Pregnancy related outcomes CG X
Neural development (GM) ME X
Child behaviour (CBCL) SR X
Cortisol (hair strands) BM X X X
Buccal swab BM X X
Blood sample BM X
Meconium (SSRI concentration) BM X
Breast milk (SSRI concentration) BM X
Int interview, SR self report, CG caregiver, BM biological materials, T0 pre-assesment, T1 baseline, T2 24 weeks of gestation, T3 36 weeks of gestation, T4 delivery,
T5 4 weeks postpartum, T6 12 weeks postpartum, T7 18 months postpartum
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Child
At 12 weeks postpartum we will perform a General
Movements (GM) assessment by taking video recordings
at home [63]. This assessment method evaluates the
function of the young nervous system.
GMs are spontaneous movements that are present
from early foetal life onwards until the end of the first
half-year of life. GMs are complex, occur frequently and
last long enough to be observed properly. If the nervous
system is impaired, GMs lose their complex and variable
character and become monotonous and poor [64].
For mapping of the SSRI exposure of the newborn, sam-
ples of meconium and breast milk (if breastfeeding) will
be collected. SSRI in meconium will be measured by a val-
idated method according to LCH guidelines on LC-MS/
MS [65]. If feasible, hair strands and a buccal swab of the
newborn will be collected at 12 weeks after birth (T6).
Long-term follow-up includes the well-established, reli-
able and valid Child Behaviour Check List 1.5-5 years, in-
cluding the Caregiver Teacher Report Form (C-TRF) and
the Language Development Survey (LDS) at 18 months
postpartum [66]. Also, permission will be asked to obtain
routine data from Centres for Childhood (CJG) until
24 months (in particular on length gain, weight gain, nor-
mal development, and any information on abnormal behav-
ioural development).
Sample size
Sample size calculation is based on the main aim of this
study, which is to demonstrate non-inferiority of pre-
ventive CT with guided discontinuation of SSRIs (STOP)
compared to continuation (GO), with respect to relapse
or recurrence of a depressive episode up to 3 months
postnatal. We will use a non-inferiority margin (toler-
ance threshold, ‘delta’) of 15 %. This is based on the as-
sumption that this excess relapse (taking into account
the possibility of restoring SSRI treatment) is still in bal-
ance with the expected beneficial effects of discontinu-
ation of SSRI for the remaining mothers. We also
anticipate that this balance is acceptable for women.
With this non-inferiority margin, and the assumption
that the overall absolute risk of relapse will be around
15 % [67], we need 178 women, given alpha .025, power
80 %, and a one-sided test. To account for some attri-
tion, we aim to include 200 women in total. Given this
sample size, we have sufficient power to demonstrate
small to moderate effect sizes of .42 or over on continu-
ous secondary outcomes. With respect to dichotomous
secondary outcomes, we will be able to detect odds ra-
tios of 1.5 or over when the base probability is .5.
Statistical analysis
Analysis will primarily be carried out according to the
intention-to-treat principle, i.e., the participants will be
analysed according to their randomized allocation, re-
gardless of the actual interventions received by the par-
ticipant. Supplementary, we will perform analyses per
protocol, i.e., according to actual SSRI use, irrespective
of randomized arm.
The primary outcome, risk (cumulative incidence up to
3 months postnatal) of relapse of depression, will be com-
pared between the randomized groups. Differences will be
assessed statistically using a one-sided Chi-Square Test at
a significance level of .025 and will be presented as a risk
difference. The remainder of statistical tests will be per-
formed two-sided at a significance level of .05.
Time to relapse will be compared between the ran-
domized groups using survival analysis. Kaplan-Meier
curves will be constructed and differences will be tested
using the log-rank test. A Cox proportional hazard
model will be used to calculate hazard ratios
Continuous outcomes, e.g., the General Movements
scores at 3 months, will be compared between the
groups using the unpaired t-test. Categorical secondary
outcomes, e.g., obstetric complications, will be tested
using Chi-Square Tests. For the continuous variables
and categorical variables that are assessed more than
twice, we will deploy linear mixed models and general-
ized linear mixed models respectively. These models use
all available data (do not exclude persons with missing
values) under the assumption of data being missing at
random, and account for within-subject correlation over
time. If despite randomization prognostically important
factors differ between the groups, they will be adjusted
for in supplemental analyses by including these factors
in the pertaining regression models.
Subgroup analyses will be undertaken according to:
Dutch/non-Dutch, nulliparous/multiparous, yes/no history
depressive disorder and/or anxiety disorder, yes/no co-
morbid anxiety symptoms or disorder. All effect parameters
will be supplied with a 95 % confidence interval.
Economic evaluation
In the present study we will also evaluate the outcome
in the two study groups (Stop and Go) from a societal,
economic perspective. It is therefore important to weigh
cost savings for both groups against their clinical value.
If relapse/recurrence incidence is within the predefined
threshold (15 %), hence non-inferiority is confirmed; a
straightforward cost minimization analysis will be exe-
cuted focussing on cost savings. However, successful ta-
pering of SSRIs will reduce SSRI use for years. Hence,
with a sensitivity analysis on maternal effects and costs
we will project cost estimations for 10 years. We expect
that the upfront investment in PCT for women with
previous psychiatric disorders will then be balanced by
reduced SSRI use and less healthcare consumption. A
previous RCT in a non-pregnant population demonstrated
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that a brief CT intervention is cost effective in remitted
depressed individuals that stop antidepressants, compared
to continuation of antidepressants [68].
If, however, relapse/recurrence incidence is higher than
the predefined tolerance threshold, thus discontinuation is
clinically inferior and rejected, a cost-effectiveness analysis
will be executed as primary analysis, which estimates the
costs avoided per additional relapse. This is the opposite
of the extra costs per prevented relapse, if the starting
point would have been no SSRI, and starting SSRI would
be considered. Regardless the relapse outcome, we will
conduct a cost utility analysis which estimates the impact
of SSRI on the costs per Quality Adjusted Life Year
(QALY), at least with a 3 month time horizon.
Discussion
The use of SSRIs during pregnancy remains a clinical
dilemma for both clinicians and patients. Given the in-
crease of SSRI use among pregnant women and studies
reporting conflicting results [7, 8, 11–14, 18, 19], there is
dire need of randomized controlled trials investigating
the use of SSRIs during pregnancy. This study will be
the first to investigate the effect of preventive cognitive
therapy with guided tapering of SSRIs from early preg-
nancy onwards as compared to continuation of SSRIs
during pregnancy. Additionally, the study focuses on
child outcomes and cost effectiveness.
Previous studies on relapse prevention showed prom-
ising results for tapering antidepressants with added re-
lapse prevention [29]. Preventive cognitive therapy
moreover showed promising long-term effects in non-
pregnant women with a history of depression [27, 28].
Preventive cognitive therapy with guided tapering of an-
tidepressants may therefore be a good alternative for
SSRI use during pregnancy.
To our knowledge, no randomized controlled trials
have been performed during pregnancy that investigated
alternative treatment options versus SSRI use. This may
be the result of the complex ethical situation of studies
in pregnant women who are taking SSRIs and must be
willing to either taper or continue SSRI use. Logistics of
a nationwide randomized controlled trial are also diffi-
cult in a multidisciplinary setting. Although a multidis-
ciplinary guideline exists, health care givers still have
different views on best practice and therefore give differ-
ent advices to their patients. This study will therefore be
as pragmatic as possible, while still providing the inter-
vention in a protocoled manner.
Results of this study will be published and will contrib-
ute to further development of (international) guidelines.
The results will provide a first step in giving pregnant
women an answer to the question whether it is better to
stop or to continue the use of SSRIs during pregnancy.
Ethics approval and consent to participate
The Medical Ethical Commission of the Erasmus Medical
Center approved this study. Participants will sign informed
consent form before participation.
Endnotes
1Relapse is defined as the re-emergence of depressive
symptoms during the remission phase, but before full
recovery. Recurrence is defined as the onset of a new
depression episode during the recovery phase or long
remission phase.
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